Silicon Valley’s Desperation and the Real Economy’s RevengeGlobal Report·Sep 15 at 10:12 AMGRI-0.54%KURA+0.34%
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic PillarsUnusual Whales·Sep 8 at 12:16 PMGRI-0.54%
GRI Bio says Phase 2a trial shows GRI-0621 lifts placebo-adjusted FVC in IPF patients at 12 weeksPUBT·Sep 8 at 12:16 PMGRI-0.54%
Commercial Milestones and AI Tailwinds: Key Shifts Across Niche Players This WeekGlobal Report·Sep 8 at 11:33 AMLWLG-0.90%VECO+1.74%
Cut the Hype: In 2026, Wall Street is Only Paying for Hard AI Infrastructure and Weight-Loss MiraclesGlobal Report·Sep 8 at 09:19 AMYSXT+8.40%SDGR-5.13%
GRI Bio highlights IPF drug candidate GRI-0621 in “Why Now” webcast ahead of ERS 2026 data presentationPUBT·Aug 27 at 01:02 PMGRI-0.54%
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 | GRI Stock NewsStockTitan·Aug 24 at 05:05 AMGRI-0.54%
GRI Bio, Inc. 2Q 2026: Net income $(1.64) M, EPS $(0.91) — 10-Q SummaryTradingView·Aug 14 at 11:51 AMGRI-0.54%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Aug 11 at 05:06 PMALMR+6.15%GRI-0.54%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jul 20 at 12:05 PMBRNS0.00%VBIO-0.90%
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis | GRI Stock NewsStockTitan·Jun 18 at 04:31 AMGRI-0.54%
